Skip to main content
Clinical Trials/NCT03591796
NCT03591796
Completed
Not Applicable

Selective High Frequency Oscillation Ventilation(HFOV) vs Conventional Mechanical Ventilation(CMV) for Neonates With Acute Respiratory Distress Syndrome(ARDS):an Multicenters Randomized Controlled Trial

Daping Hospital and the Research Institute of Surgery of the Third Military Medical University1 site in 1 country386 target enrollmentDecember 31, 2024

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Acute Respiratory Distress Syndrome
Sponsor
Daping Hospital and the Research Institute of Surgery of the Third Military Medical University
Enrollment
386
Locations
1
Primary Endpoint
Death
Status
Completed
Last Updated
9 months ago

Overview

Brief Summary

Acute respiratory distress syndrome (ARDS) in neonates has been defined in 2017.The death rate is over 50%. HFOV and CMV are two main invasive ventilation strategies. However, which one is better needing to be further elucidated.

Detailed Description

Severe acute respiratory distress syndrome (ARDS) is one of the serious complications in critically ill neonates. It can result in severe hypoxemia refractory to mechanical ventilation. Usually, invasive ventilation with low parameters is enough for neonates with mild and moderate ARDS. And extracorporeal membrane oxygenation is used to neonates with severe ARDS. However, extracorporeal membrane oxygenation can also lead to high death rate and need more technique and conditions. Mechanical ventilation with higher parameters was a substitute for such situations, but the death rate, complications and injuries of higher parameters is unknown. The purpose of the present study was to compare HFOV with CMV as invasive respiratory support strategies on decrease the mortality and morbidities in neonate with ARDS.

Registry
clinicaltrials.gov
Start Date
December 31, 2024
End Date
December 31, 2024
Last Updated
9 months ago
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Sponsor
Daping Hospital and the Research Institute of Surgery of the Third Military Medical University
Responsible Party
Principal Investigator
Principal Investigator

Chen Long,MD

Principal Investigator

Children's Hospital of Chongqing Medical University

Eligibility Criteria

Inclusion Criteria

  • Gestational age (GA) between 25+0 and 34+0 weeks;
  • Assisted with CMV within 12 h after birth;
  • Diagnosis with ARDS;
  • Stabilization for 2 hours before randomization: FiO2 0.40, mean airway pressure (MAP) 10-14 cmH2O, ≤ 40 bpm of respiratory rate, 90%-94% of SpO2, pH \> 7.20, PaCO2 60 mmHg and \> 35% of hematocrit

Exclusion Criteria

  • parents' decision not to participate;
  • Major congenital anomalies or chromosomal abnormalities;
  • Upper respiratory tract abnormalities;
  • need for surgery before randomization;
  • Grade Ⅲ-IV-intraventricular hemorrhage (IVH).

Outcomes

Primary Outcomes

Death

Time Frame: 28 days after birth or 36 weeks'gestational age or before discharge

the included preterm infants were dead

the incidence of bronchopulmonary dysplasia (BPD)

Time Frame: 28 days after birth or 36 weeks'gestational age

the included neonate was diagnosed with BPD

Secondary Outcomes

  • the incidence of neonatal necrotizing enterocolitis(NEC)(28 days after birth or 36 weeks'gestational age or before discharge)
  • the incidence of retinopathy of prematurity(ROP)(28 days after birth or 36 weeks'gestational age or before discharge)
  • Intraventricular hemorrhage(28 days after birth or 36 weeks'gestational age or before discharge)
  • composite mortality/BPD(28 days after birth or 36 weeks'gestational age or before discharge)
  • the incidence of airleak(28 days after birth or 36 weeks'gestational age or before discharge)

Study Sites (1)

Loading locations...

Similar Trials